Top 15 Life Science VC (Venture Capital) Funds in Norway in January 2026

Portfolio highlights

• Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Kongsberg Ferrotech — Kongsberg Ferrotech offers game-changing robotic services for inspection, repair, and maintenance (IRM) of underwater installations

Portfolio highlights

• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy'​ is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
• Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Portfolio highlights

• Filics — A scalable transport solution for standardized load carriers with a minimum energy footprint
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.

Portfolio highlights

• SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
• Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
• Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.

Portfolio highlights

• Kure Cells — Kure Cells is a biotechnology company developing rapid-manufacturing platforms for CAR-T and gene-modified cell therapies.

Portfolio highlights

• Hazen.ai — Enhance safety with our AI-powered camera, providing real-time monitoring and precise violation detection. This technology empowers authorities to enforce traffic laws effectively, ensuring safer roads for all.
• FalconViz — FalconViz is a Saudi registered company focused on 3D surveying and mapping by Unmanned Aerial Systems (UAS) with autonomous integration of planes, copters and 3D software solutions.
• UnitX — Automate inspection in-line for better yield

Portfolio highlights

• DNA Script — DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
• AAVantgarde Bio — AAVantgarde Bio is developing gene therapies for inherited retinal disorders.
• Excelsior Sciences — Rebuilding the World, From the Bottom Up

Portfolio highlights

• CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
• Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
• Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

Portfolio highlights

• SeaForester — Restoring the forgotten forests in our ocean.
• Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
• Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.

Portfolio highlights

• Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
• Iris.ai — helps enterprises deploy secure, high-quality Agentic AI. Simplify data ingestion, orchestration, retrieval and evaluation with tailored workflows at scale.

Portfolio highlights

• APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
• Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
• Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Portfolio highlights

• Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Portfolio highlights

• Nomono — Nomono delivers studio-grade spoken audio with next-gen wireless tools. Record anywhere, auto-enhance with AI, and edit in the cloud - trusted by storytellers
• Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
• Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.

Portfolio highlights

• Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.

Portfolio highlights

• Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.